Significant control over Akebia Therapeutics by individual investors implies that the general public has more power to influence management and governance-related decisions

37% of the business is held by the top 25 shareholders

Institutions own 43% of Akebia Therapeutics

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Every investor in Akebia Therapeutics, Inc. (NASDAQ:AKBA) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are individual investors with 55% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

Meanwhile, institutions make up 43% of the company’s shareholders. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones.

Let’s delve deeper into each type of owner of Akebia Therapeutics, beginning with the chart below.

Check out our latest analysis for Akebia Therapeutics

NasdaqCM:AKBA Ownership Breakdown September 6th 2025

What Does The Institutional Ownership Tell Us About Akebia Therapeutics?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

Akebia Therapeutics already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Akebia Therapeutics, (below). Of course, keep in mind that there are other factors to consider, too.

NasdaqCM:AKBA Earnings and Revenue Growth September 6th 2025

We note that hedge funds don’t have a meaningful investment in Akebia Therapeutics. The company’s largest shareholder is BlackRock, Inc., with ownership of 6.9%. With 5.5% and 3.0% of the shares outstanding respectively, The Vanguard Group, Inc. and State Street Global Advisors, Inc. are the second and third largest shareholders. In addition, we found that John Butler, the CEO has 0.6% of the shares allocated to their name.

A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock’s expected performance. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.